-$0.95 EPS Expected for Sierra Oncology, Inc. (NASDAQ:SRRA) This Quarter

Wall Street brokerages forecast that Sierra Oncology, Inc. (NASDAQ:SRRAGet Rating) will post earnings per share of ($0.95) for the current quarter, according to Zacks. Zero analysts have made estimates for Sierra Oncology’s earnings. The highest EPS estimate is ($0.88) and the lowest is ($1.02). Sierra Oncology posted earnings per share of ($1.67) in the same quarter last year, which suggests a positive year-over-year growth rate of 43.1%. The company is scheduled to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Sierra Oncology will report full-year earnings of ($4.79) per share for the current fiscal year, with EPS estimates ranging from ($5.91) to ($3.90). For the next financial year, analysts expect that the firm will report earnings of ($3.60) per share, with EPS estimates ranging from ($4.42) to ($3.10). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Sierra Oncology.

Sierra Oncology (NASDAQ:SRRAGet Rating) last issued its quarterly earnings data on Thursday, March 10th. The biotechnology company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($1.60) by ($0.07).

A number of research firms have commented on SRRA. Lifesci Capital downgraded shares of Sierra Oncology from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 13th. Zacks Investment Research downgraded shares of Sierra Oncology from a “buy” rating to a “hold” rating in a research report on Wednesday. Oppenheimer downgraded shares of Sierra Oncology from an “outperform” rating to a “market perform” rating and boosted their price target for the stock from $45.00 to $55.00 in a research report on Thursday, April 14th. HC Wainwright downgraded shares of Sierra Oncology from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $51.00 to $55.00 in a report on Wednesday, April 13th. Finally, Jefferies Financial Group downgraded shares of Sierra Oncology from a “buy” rating to a “hold” rating and boosted their target price for the stock from $39.00 to $55.00 in a report on Thursday, April 14th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $53.00.

In related news, insider William D. Turner sold 3,453 shares of the business’s stock in a transaction that occurred on Thursday, March 17th. The shares were sold at an average price of $37.06, for a total transaction of $127,968.18. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, General Counsel Mary Christina Thomson sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $35.14, for a total transaction of $70,280.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,553 shares of company stock worth $201,957. 67.68% of the stock is currently owned by insiders.

A number of hedge funds have recently bought and sold shares of SRRA. Frazier Life Sciences Management L.P. bought a new stake in Sierra Oncology in the first quarter worth approximately $75,067,000. Deep Track Capital LP acquired a new stake in shares of Sierra Oncology in the fourth quarter worth $13,209,000. Frazier Management LLC lifted its stake in shares of Sierra Oncology by 57.2% in the fourth quarter. Frazier Management LLC now owns 1,264,861 shares of the biotechnology company’s stock worth $27,498,000 after buying an additional 460,194 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Sierra Oncology in the first quarter worth $14,134,000. Finally, BlackRock Inc. lifted its stake in shares of Sierra Oncology by 1,812.7% in the first quarter. BlackRock Inc. now owns 448,430 shares of the biotechnology company’s stock worth $14,372,000 after buying an additional 424,985 shares during the last quarter. 99.30% of the stock is owned by institutional investors.

NASDAQ:SRRA traded up $0.02 during mid-day trading on Friday, hitting $54.75. The stock had a trading volume of 199,288 shares, compared to its average volume of 402,407. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -8.09 and a beta of 0.01. The company has a 50 day simple moving average of $46.06 and a 200-day simple moving average of $32.47. Sierra Oncology has a 52 week low of $14.91 and a 52 week high of $54.97. The company has a current ratio of 21.27, a quick ratio of 21.27 and a debt-to-equity ratio of 0.02.

Sierra Oncology Company Profile (Get Rating)

Sierra Oncology, Inc, a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor.

Further Reading

Get a free copy of the Zacks research report on Sierra Oncology (SRRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.